Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy

Optimal Medical Therapy with or without PCI for Stable Coronary Disease

Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699 · see citing works

Effects of torcetrapib in patients at high risk for coronary events

Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · see citing works

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works

Effects of dalcetrapib in patients with a recent acute coronary syndrome

Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · see citing works

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799 · see citing works

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664 · see citing works

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037 · see citing works

Atherosclerosis

Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211 · see citing works

The changing landscape of atherosclerosis

Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873 · see citing works

Chronic variable stress activates hematopoietic stem cells

Heidt, T., Sager, H. B., Courties, G., Dutta, P., Iwamoto, Y., Zaltsman, A., von zur Muhlen, C., Bode, C., Fricchione, G. L., Denninger, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3589 · Cited by 803 · see citing works

Monocyte-macrophages and T cells in atherosclerosis

Tabas, I., & Lichtman, A. H. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.008 · Cited by 646 · see citing works

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625 · see citing works

Animal models of atherosclerosis

Emini Veseli, B., Perrotta, P., De Meyer, G. R. A., Roth, L., Van der Donckt, C., Martinet, W., & De Meyer, G. R. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.010 · Cited by 548 · see citing works

Metformin and inflammation: its potential Beyond glucose-lowering effect

Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450 · see citing works

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

Bauersachs, R., Zeymer, U., Brière, J.-B., Marre, C., Bowrin, K., & Huelsebeck, M. (2019) · Cardiovascular Therapeutics · doi:10.1155/2019/8295054 · Cited by 449 · see citing works

Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques

Hutcheson, J. D., Goettsch, C., Bertazzo, S., Maldonado, N., Ruiz, J. L., Goh, W., Yabusaki, K., Faits, T., Bouten, C., Franck, G., et al. (2016) · Nature Materials · doi:10.1038/nmat4519 · Cited by 419 · see citing works

Exercise-related acute cardiovascular events and potential deleterious adaptations following long-term exercise training: placing the risks into perspective – an update. A Scientific Statement from the American Heart Association

Franklin, B. A., Thompson, P. D., Al-Zaiti, S. S., Albert, C. M., Hivert, M.-F., Levine, B. D., Lobelo, F., Madan, K., Sharrief, A. Z., Eijsvogels, T. M. H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000749 · Cited by 410 · see citing works

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · see citing works

Relationship between lifelong exercise volume and coronary atherosclerosis in athletes.

Aengevaeren, V. L., Mosterd, A., Braber, T. L., Prakken, N. H. J., Doevendans, P. A., Grobbee, D. E., Thompson, P. D., Eijsvogels, T. M. H., & Velthuis, B. K. (2017) · Circulation · doi:10.1161/circulationaha.117.027834 · Cited by 309 · see citing works

Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial

Toledo, E., Hu, F. B., Estruch, R., Buil-Cosiales, P., Corella, D., Salas-Salvadó, J., Covas, M. I., Arós, F., Gómez-Gracia, E., Fiol, M., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-207 · Cited by 289 · see citing works

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization

Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307983 · Cited by 227 · see citing works

The arterial microenvironment: the where and why of atherosclerosis

Yurdagul, A., Finney, A. C., Woolard, M. D., & Orr, A. W. (2016) · Biochemical Journal · doi:10.1042/bj20150844 · Cited by 185 · see citing works

Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques

Langley, S. R., Willeit, K., Didangelos, A., Matic, L. P., Skroblin, P., Barallobre-Barreiro, J., Lengquist, M., Rungger, G., Kapustin, A., Kedenko, L., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci86924 · Cited by 174 · see citing works

Periodontal therapy and cardiovascular risk

Orlandi, M., Graziani, F., & D'Aiuto, F. (2020) · Periodontology 2000 · doi:10.1111/prd.12299 · Cited by 155 · see citing works

Defective autophagy in atherosclerosis: to die or to senesce?

Grootaert, M. O. J., Roth, L., Schrijvers, D. M., De Meyer, G. R. Y., & Martinet, W. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7687083 · Cited by 147 · see citing works

Effects of moderate-to-severe obstructive sleep apnea on the clinical manifestations of plaque vulnerability and the progression of coronary atherosclerosis in patients with acute coronary syndrome

Nakashima, H., Kurobe, M., Minami, K., Furudono, S., Uchida, Y., Amenomori, K., Nunohiro, T., Takeshita, S., & Maemura, K. (2015) · European Heart Journal: Acute Cardiovascular Care · doi:10.1177/2048872614530865 · Cited by 71 · see citing works

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial

Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26 · see citing works

Associations between Inflammatory Markers and Subclinical Atherosclerosis in Middle-aged White, Japanese-American and Japanese Men: The ERA-JUMP Study

Nagasawa, S.-Y., Ohkubo, T., Masaki, K., Barinas-Mitchell, E., Miura, K., Seto, T., El-Saed, A., Kadowaki, T., Willcox, B. J., Edmundowicz, D., et al. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.23580 · Cited by 26 · see citing works

Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus

Liu, Z., Xu, Y., Hao, H., Yin, C., Xu, J., Li, J., Wang, Y., & Xu, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.140 · Cited by 16 · see citing works

Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study

Ilardi, F., Gargiulo, G., Schiattarella, G. G., Giugliano, G., Paolillo, R., Menafra, G., De Angelis, E., Scudiero, L., Franzone, A., Stabile, E., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.03.004 · Cited by 16 · see citing works

Objectively assessed physical activity, adiposity, and inflammatory markers in people with type 2 diabetes

Hamer, M., Hackett, R. A., Bostock, S., Lazzarino, A. I., Carvalho, L. A., & Steptoe, A. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000030 · Cited by 12 · see citing works